... at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, .... NERLYNX is a registered trademark of Puma Biotechnology, Inc.
News
- plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer
- BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce ...
- Why These Breast Cancer Study Results Look So Promising
Puma Biotechnology Inc. (NASDAQ: PBYI) shares made a handy gain early on Thursday after the company presented updated results from its Phase ...
- Experimental Drugs Achieve Unusually Good Results Against Hard-To-Treat Advanced Breast ...
On Wednesday, data from that drug are being presented at the San Antonio Breast ... Early-stage biotech companies are almost always raising money.
- Puma Bio up 5% premarket on Nerlynx data in heavily pretreated breast cancer patients
Puma Biotechnology (NASDAQ:PBYI) is up 5% premarket on light volume in response to results from an ongoing open-label Phase 2 basket study, SUMMIT, ... The data were presented at the San Antonio Breast Cancer Symposium.